

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited
翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

CLINICAL TRIAL APPROVAL OF “IBREXAFUNGERP TABLETS”

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) is pleased to announce that “Ibrexafungerp Tablets” (the “**Product**”) has been granted a clinical trial approval issued by the National Medical Products Administration of the People’s Republic of China. The Group will conduct phase 3 clinical trial for vulvovaginal candidiasis (VVC) in China.

As disclosed in the announcement of the Company dated February 17, 2021, Hansoh (Shanghai) Healthtech Company Limited* (翰森(上海)健康科技有限公司) and Jiangsu Hansoh Pharmaceutical Group Co., Ltd.* (江蘇豪森藥業集團有限公司), both wholly-owned subsidiaries of the Company, obtained an exclusive license from SCYNEXIS, Inc. (NASDAQ: SCYX) to research, develop and commercialize Ibrexafungerp in the People’s Republic of China (including Hong Kong, Macau and Taiwan). As at the date of this announcement, the Product has been approved by the U.S. Food and Drug Administration for the treatment of vulvovaginal candidiasis (VVC), being the first new antifungal class in over 20 years, as well as the first and only non-azole treatment for vaginal yeast infections.

About Ibrexafungerp

Ibrexafungerp is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids. This agent combines the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations. Ibrexafungerp is in late-stage development for multiple indications, including fungal infections caused primarily by *Candida* (including *C. auris*) and *Aspergillus* species in hospitalized patients. It has demonstrated broad-spectrum antifungal activity, *in vitro* and *in vivo*, against multidrug-resistant pathogens, including azole- and echinocandin-resistant strains.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, December 15, 2021

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.

* *For identification purposes only*